Drug Profile
CDP 1050
Alternative Names: CDP-1050Latest Information Update: 07 Jan 2011
Price :
$50
*
At a glance
- Originator Duke University; Johns Hopkins University
- Developer Cordex Pharma
- Class Heart failure therapies
- Mechanism of Action Nitric oxide donors; Reactive oxygen species inhibitors; Ryanodine receptor calcium release channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Heart failure
Most Recent Events
- 20 Feb 2009 Phase-I clinical trials in Heart failure in USA (unspecified route)